Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYGK1D)

Drug Name

OTL-300 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hemoglobin subunit beta (HBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LentiGlobin	DMSCGM8	Beta thalassemia	3A50.2	Phase 3	[3]
PF-07059013	DMSDVKK	Sickle-cell disorder	3A51	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03275051) Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Orchard Therapeutics.
3	Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81.
4	PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. Am J Hematol. 2021 Aug 1;96(8):E272-E275.